Docket Number:11A-1050215
Inventor:Ching- Shih Chen(Institute of Biological Chemistry), Yi-Ling Lin(Institute of Biomedical Sciences), Appaso Jadhav (OSU)
IP Status:pending
Abstract:
This invention disclosure describes a novel class of host cell-directed anti-dengue agents that act on virus-infected cells to trigger cellular responses to suppress viral infection. First, their mode of action is independent of virus mutations associated with antiviral resistance (the so-called resistant variants). Second, the antiviral activity is broad-spectrum. Moreover, using a representative agent, we demonstrated the in vivo efficacy of this host cell-targeted strategy to prolong the survival of dengue virus-infected mice.
Fields of Application:
dengue-related diseases treatment and prevevtion
Advantages when compared to the existing technologies:
The anti-viral mechanism of these novel agents is host cell-directed, and is distinct from that of conventionalanti-viral agents. Therefore, these antiviral agents are effective against a broad-spectrum of virusese independent of virus mutations.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you.
